L-lysine aescinat 0.1%, 5 ml of solution for injection 10s
- $59.20
The instruction for medical use
of L-LIZINA ESTSINAT medicine
the Trade name
of L-LIZINA ESTSINAT
the International unlicensed name
Is not present
the Dosage form
Solution for injections, 1 mg/ml
contains Structure of 1 ml of solution:
active agent - an estsinat L-lysine (in terms of 100% substance) - 1 mg,
excipients - ethanol of 96%, propylene glycol, water for injections
the Description
Transparent, colourless liquid
Pharmacotherapeutic group
Vasoprotectives. The drugs reducing permeability of capillaries. The other drugs reducing permeability of capillaries
the ATX C05CX Code
the Pharmacological
Pharmacodynamics properties.
Drug has the anti-inflammatory, antiedematous and anesthetizing effect. Estsin lowers activity of lizosomalny hydrolases that prevents splitting of mucopolysaccharides in walls of capillaries and in connective tissue which surrounds them, and thus normalizes the increased vascular and fabric permeability and renders the anti-exudative (antiedematous), anti-inflammatory and anesthetizing action. Drug raises a tone of vessels, renders moderate immunocorrective and hypoglycemic effects.
Pharmacokinetics.
It was not studied.
Indications
are posttraumatic, intra- and postoperative hypostases of any localization: hypostases of a head and spinal cord, including with intracraneal hemorrhages, increase in intracranial pressure and the phenomena of hypostasis swelling, likvorno-venous disturbances at chronic disturbances of cerebral circulation and vegeto-vascular dystonia
- the hypostases of soft tissues with involvement of the musculoskeletal system which are followed by local disorders of their blood supply and a pain syndrome
- hydropic pain syndromes of a backbone, trunk, extremities
- the heavy disturbances of venous blood circulation of the lower extremities in acute thrombophlebitis which are followed by a hydropic and inflammatory syndrome.
The route of administration and doses
administer the Drug strictly intravenously slowly (intra arterial introduction is not allowed!) in a daily dose of 5-10 ml. Intravenous drop administration is recommended. At preparation of infusion solution of a L-lysine estsinat dissolve 0.9% of solution of sodium of chloride in 15-50 ml.
At states, life-threatening the patient (an acute craniocereberal injury, intra- and postoperative hypostases of a head and spinal cord with the hypostasis swelling phenomena, puffiness of the big sizes owing to extensive injuries of soft tissues and the musculoskeletal system), the daily dose is increased to 20 ml, having divided into 2 introductions. The maximum daily dose for adult 25 ml.
At children the single dose makes: 1-5 years 0, 22 mg of a L-lysine of the estsinat for 1 kg of body weight, 5-10 years of 0.18 mg/kg, 10 years are also more senior than 0.15 mg/kg of body weight. The drug is administered by 2 times a day.
Duration of a course of treatment is from 2 to 8 days, depending on a condition of the patient and efficiency of therapy.
Side effects
At individual hypersensitivity to an estsin at certain patients are possible:
- allergic reactions: skin rash (papular, petekhialny, erythematic), an itching, a dermahemia of the person, fever, urticaria, in isolated cases a Quincke's edema, an acute anaphylaxis,
- from the central and peripheral nervous system: a headache, dizziness, a tremor, paresthesias, in isolated cases shaky gait, balance disturbance, a short-term loss of consciousness,
- from a liver and a biliary system: increase in level of transaminases and bilirubin,
- from digestive tract: nausea, in isolated cases vomiting, diarrhea, an abdominal pain,
- from a cardiovascular system: arterial hypotension, arterial hypertension, tachycardia, pain behind a breast,
- from respiratory organs: in isolated cases feeling of shortage of air, an asthma, a bronkhoobstruktion, dry cough,
- local reactions: burning sensation on the vein course at introduction, phlebitis, pain and hypostasis in the injection site,
- others: general weakness, fever, feeling of heat, back pain, perspiration.
Contraindications
- hypersensitivity to a L-lysine to an estsinat and/or other components of drug
- heavy renal failures
- heavy abnormal liver functions
- pregnancy
- the lactation period
- children's age till 1 year.
Medicinal interactions
At treatment of a L-lysine estsinaty prescribing of other medicines at the corresponding indications is possible (anti-inflammatory, analgetics, antimicrobic).
Drug should not be used along with aminoglycosides because of a possibility of increase in their nephrotoxicity. In case of long therapy it is necessary to carry out by anticoagulants which was carried out before purpose of a L-lysine of the estsinat or in need of simultaneous use of a L-lysine of the estsinat and anticoagulants dose adjustment of the last (to reduce a dose) and to control the prothrombin ratio.
Linking of an estsin with protein of plasma is at a loss at simultaneous use of antibiotics of a tsefalosporinovy row that can increase concentration of a free estsin in blood with risk of development of side effects of the last.
Special instructions
At certain patients with gepatokholetsistity when prescribing drug perhaps short-term increase in activity of transaminases and bilirubin (direct fraction) that does not make threat for patients and does not demand drug withdrawal.
Use during pregnancy and feeding by a breast. Use of drug during pregnancy and feeding by a breast contraindicated (for the period of treatment it is necessary to stop feeding by a breast).
Children. Drug is contraindicated to children aged till 1 year.
Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms. At the moment there are no messages, however at use of drug it is necessary to consider a possibility of development of expected side reactions from nervous system.
Overdose
Symptoms: heat, tachycardia, a menorrhagia, nausea, heartburn, pain in epigastriums.
Treatment: symptomatic therapy.
A form of release and packing
On 5 ml of drug in an ampoule or an ampoule with a ring of a break of yellow color or with a break point.
On 5 ampoules put in blister strip packaging from a film polyvinylchloride or on 5 ampoules put in blister strip packaging from a film polyvinylchloride, covered with a film.
On the 2nd blister strip packagings together with the instruction for medical use in the state and Russian languages and the scarificator ampoule put in a pack from cardboard.
When using ampoules with a point or a ring of breaking the scarificators do not invest.
To Store storage conditions out of children's reach!
To store in the place protected from light, at a temperature from 15 With up to 25 C.
2 years
not to apply a period of storage after expiry date.
Prescription status
According to the prescription
JSC Galichpharm Ukraina Producer, 79024, Lviv, Opryshkovskaya St., 6/8
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products:
Representative office of Arterium corporation in
Republic of Kazakhstan 050060, Almaty, Al-Farabi Avenue 97, 3 entrance, office 54
Ph. / fax: 8 (727) 315-82-09, 8 (727) 315-82-10,
E-mail: Almaty@arterium.ua
of L-LIZINA ESTSINAT medicine
the Trade name
of L-LIZINA ESTSINAT
the International unlicensed name
Is not present
the Dosage form
Solution for injections, 1 mg/ml
contains Structure of 1 ml of solution:
active agent - an estsinat L-lysine (in terms of 100% substance) - 1 mg,
excipients - ethanol of 96%, propylene glycol, water for injections
the Description
Transparent, colourless liquid
Pharmacotherapeutic group
Vasoprotectives. The drugs reducing permeability of capillaries. The other drugs reducing permeability of capillaries
the ATX C05CX Code
the Pharmacological
Pharmacodynamics properties.
Drug has the anti-inflammatory, antiedematous and anesthetizing effect. Estsin lowers activity of lizosomalny hydrolases that prevents splitting of mucopolysaccharides in walls of capillaries and in connective tissue which surrounds them, and thus normalizes the increased vascular and fabric permeability and renders the anti-exudative (antiedematous), anti-inflammatory and anesthetizing action. Drug raises a tone of vessels, renders moderate immunocorrective and hypoglycemic effects.
Pharmacokinetics.
It was not studied.
Indications
are posttraumatic, intra- and postoperative hypostases of any localization: hypostases of a head and spinal cord, including with intracraneal hemorrhages, increase in intracranial pressure and the phenomena of hypostasis swelling, likvorno-venous disturbances at chronic disturbances of cerebral circulation and vegeto-vascular dystonia
- the hypostases of soft tissues with involvement of the musculoskeletal system which are followed by local disorders of their blood supply and a pain syndrome
- hydropic pain syndromes of a backbone, trunk, extremities
- the heavy disturbances of venous blood circulation of the lower extremities in acute thrombophlebitis which are followed by a hydropic and inflammatory syndrome.
The route of administration and doses
administer the Drug strictly intravenously slowly (intra arterial introduction is not allowed!) in a daily dose of 5-10 ml. Intravenous drop administration is recommended. At preparation of infusion solution of a L-lysine estsinat dissolve 0.9% of solution of sodium of chloride in 15-50 ml.
At states, life-threatening the patient (an acute craniocereberal injury, intra- and postoperative hypostases of a head and spinal cord with the hypostasis swelling phenomena, puffiness of the big sizes owing to extensive injuries of soft tissues and the musculoskeletal system), the daily dose is increased to 20 ml, having divided into 2 introductions. The maximum daily dose for adult 25 ml.
At children the single dose makes: 1-5 years 0, 22 mg of a L-lysine of the estsinat for 1 kg of body weight, 5-10 years of 0.18 mg/kg, 10 years are also more senior than 0.15 mg/kg of body weight. The drug is administered by 2 times a day.
Duration of a course of treatment is from 2 to 8 days, depending on a condition of the patient and efficiency of therapy.
Side effects
At individual hypersensitivity to an estsin at certain patients are possible:
- allergic reactions: skin rash (papular, petekhialny, erythematic), an itching, a dermahemia of the person, fever, urticaria, in isolated cases a Quincke's edema, an acute anaphylaxis,
- from the central and peripheral nervous system: a headache, dizziness, a tremor, paresthesias, in isolated cases shaky gait, balance disturbance, a short-term loss of consciousness,
- from a liver and a biliary system: increase in level of transaminases and bilirubin,
- from digestive tract: nausea, in isolated cases vomiting, diarrhea, an abdominal pain,
- from a cardiovascular system: arterial hypotension, arterial hypertension, tachycardia, pain behind a breast,
- from respiratory organs: in isolated cases feeling of shortage of air, an asthma, a bronkhoobstruktion, dry cough,
- local reactions: burning sensation on the vein course at introduction, phlebitis, pain and hypostasis in the injection site,
- others: general weakness, fever, feeling of heat, back pain, perspiration.
Contraindications
- hypersensitivity to a L-lysine to an estsinat and/or other components of drug
- heavy renal failures
- heavy abnormal liver functions
- pregnancy
- the lactation period
- children's age till 1 year.
Medicinal interactions
At treatment of a L-lysine estsinaty prescribing of other medicines at the corresponding indications is possible (anti-inflammatory, analgetics, antimicrobic).
Drug should not be used along with aminoglycosides because of a possibility of increase in their nephrotoxicity. In case of long therapy it is necessary to carry out by anticoagulants which was carried out before purpose of a L-lysine of the estsinat or in need of simultaneous use of a L-lysine of the estsinat and anticoagulants dose adjustment of the last (to reduce a dose) and to control the prothrombin ratio.
Linking of an estsin with protein of plasma is at a loss at simultaneous use of antibiotics of a tsefalosporinovy row that can increase concentration of a free estsin in blood with risk of development of side effects of the last.
Special instructions
At certain patients with gepatokholetsistity when prescribing drug perhaps short-term increase in activity of transaminases and bilirubin (direct fraction) that does not make threat for patients and does not demand drug withdrawal.
Use during pregnancy and feeding by a breast. Use of drug during pregnancy and feeding by a breast contraindicated (for the period of treatment it is necessary to stop feeding by a breast).
Children. Drug is contraindicated to children aged till 1 year.
Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms. At the moment there are no messages, however at use of drug it is necessary to consider a possibility of development of expected side reactions from nervous system.
Overdose
Symptoms: heat, tachycardia, a menorrhagia, nausea, heartburn, pain in epigastriums.
Treatment: symptomatic therapy.
A form of release and packing
On 5 ml of drug in an ampoule or an ampoule with a ring of a break of yellow color or with a break point.
On 5 ampoules put in blister strip packaging from a film polyvinylchloride or on 5 ampoules put in blister strip packaging from a film polyvinylchloride, covered with a film.
On the 2nd blister strip packagings together with the instruction for medical use in the state and Russian languages and the scarificator ampoule put in a pack from cardboard.
When using ampoules with a point or a ring of breaking the scarificators do not invest.
To Store storage conditions out of children's reach!
To store in the place protected from light, at a temperature from 15 With up to 25 C.
2 years
not to apply a period of storage after expiry date.
Prescription status
According to the prescription
JSC Galichpharm Ukraina Producer, 79024, Lviv, Opryshkovskaya St., 6/8
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products:
Representative office of Arterium corporation in
Republic of Kazakhstan 050060, Almaty, Al-Farabi Avenue 97, 3 entrance, office 54
Ph. / fax: 8 (727) 315-82-09, 8 (727) 315-82-10,
E-mail: Almaty@arterium.ua
Related Products
Halychpharm (Ukraine)
Thiotriazoline 2.5% / 2 ml 10s solution for intramuscular and intravenous administration
$26.10
Out Of Stock
Borshchahivskiy CPP/BCPP (Ukraine)
Corvitin 0.5g 5's lyophilized powder for solution for injection
$165.80
